An implementation study of treatment optimization recommendations comparing subjects continuing treatment with IFN-β-1a 30 Mcg Qw IM (Avonex) or glatiramer acetate 20 mg Qd SC (Copaxone) to those randomized to IFN-beta-1a 44 Mcg Tiw SC (Rebif), in a multicenter study of subjects with relapsing remitting multiple sclerosis currently on disease-modifying therapy

Trial Profile

An implementation study of treatment optimization recommendations comparing subjects continuing treatment with IFN-β-1a 30 Mcg Qw IM (Avonex) or glatiramer acetate 20 mg Qd SC (Copaxone) to those randomized to IFN-beta-1a 44 Mcg Tiw SC (Rebif), in a multicenter study of subjects with relapsing remitting multiple sclerosis currently on disease-modifying therapy

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2013

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top